| 产品描述: | Elexacaftor (VX-445, Compound 1) 是一种神经纤维化跨膜电导调因子 ( CFTR ) 校正剂。Elexacaftor (VX-445, Compound 1) 促进CFTR的加工和转运,增加CFTR。 |
| 靶点: |
CFTR;CFTR;Autophagy |
| 体外研究: |
Elexacaftor (VX-445) is a next-generation cystic fibrosis transmembrane conductance regulator (CFTR) corrector designed to restore Phe508del CFTR protein function. Elexacaftor (VX-445) has the potential to treat cystic fibrosis. VX-445-Tezacaftor-VX-770 significantly improves Phe508del CFTR protein processing, trafficking, and chloride transport to a greater extent than any two of these agents in dual combination. |
| 参考文献: |
1.Alexander Russell Abela, et al. MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR , PHARMACEUTICAL COMPOSITIONS , METHODS OF TREATMENT , AND PROCESS FOR MAKING THE MODULATOR. US 20180162839 A1. 2. Keating D, et al. VX-445-Tezacaftor-VX-770 in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018 Oct 25;379(17):1612-1620. [Content Brief] |
| 溶解性: |
Souble in DMSO |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.673 ml |
8.366 ml |
16.732 ml |
| 5 mM |
0.335 ml |
1.673 ml |
3.346 ml |
| 10 mM |
0.167 ml |
0.837 ml |
1.673 ml |
| 50 mM |
0.033 ml |
0.167 ml |
0.335 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |